Home › Funds › Eversept Partners, LP › CTMX
Eversept Partners, LP position in CTMX
CYTOMX THERAPEUTICS INC. · Health Care
Eversept Partners, LP reported holding 3,558,497 shares of CTMX (CYTOMX THERAPEUTICS INC.) in its Q2 2026 13F filing — a position valued at US$13.3M, representing 0.70% of its reported portfolio and ranking #39 among its reported holdings. Eversept Partners, LP has disclosed CTMX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Eversept Partners, LP's CTMX position evolved
Eversept Partners, LP first disclosed a stake in CTMX in Q4 2025 at 2,507,090 shares (US$10.7M). The position peaked in Q1 2026 at 3,188,514 shares, worth US$15.0M. Across 3 filings, Eversept Partners, LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,558,497 shares valued at US$13.3M — an increase of 369,983 shares quarter over quarter.. Notable position changes include a 27% increase in Q1 2026 (shares fell 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 2.51M | $10.68M | New |
| Q1 2026 | 3.19M | $14.99M | Add |
| Q2 2026 | 3.56M | $13.34M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CTMX and 13F data
CTMX (CYTOMX THERAPEUTICS INC.) is a Health Care company. 45 other funds we track also report a position in CTMX — the largest reported positions include Kynam Capital Management, LP (US$81.4M), PERCEPTIVE ADVISORS LLC (US$39.1M), Venrock Adviser, LLC (US$18.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CTMX
- Kynam Capital Management, LP 21.70M sh · $81.39M · Q2 2026
- PERCEPTIVE ADVISORS LLC 10.44M sh · $39.15M · Q2 2026
- Venrock Adviser, LLC 4.98M sh · $18.68M · Q2 2026
- Elmind Capital, LP 4.55M sh · $17.06M · Q2 2026
- Nextech Invest Ltd. 4.45M sh · $16.69M · Q2 2026
- ADAR1 Capital Management, LLC 3.37M sh · $12.62M · Q2 2026
- Seven Fleet Capital Management LP 1.09M sh · $4.07M · Q2 2026
- Ally Bridge Group (NY) LLC 775.00K sh · $2.91M · Q2 2026
More on Eversept Partners, LP
FAQ
How long has Eversept Partners, LP held CTMX?
Eversept Partners, LP has disclosed CTMX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Eversept Partners, LP's current position in CTMX?
As of Q2 2026, Eversept Partners, LP holds 3.56M shares of CTMX (CYTOMX THERAPEUTICS INC.), valued at $13.34M, representing 0.70% of its reported portfolio and ranking #39.
Has Eversept Partners, LP been buying or selling CTMX?
In the latest 13F filing (Q2 2026), Eversept Partners, LP increased its position in CTMX. The position peaked in Q1 2026 at 3.19M shares.
Which other funds hold CTMX?
Other major institutional holders of CTMX include Kynam Capital Management, LP, PERCEPTIVE ADVISORS LLC, Venrock Adviser, LLC, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.